critical care emergency News
-
HORIBA Medical welcomes the latest member of the new Yumizen H500 family
As a result of a growing research and development program, HORIBA Medical has recently developed two new products that aim to better meet the needs of today's clinical laboratories : The Yumizen H500 OT ‘Open Tube’ with flexible sampling to accommodate all sample types, particularly for rapid screening in critical care, emergency care and pediatric clinics. The new released ...
-
Abionic Successfully Raises CHF20 Million in Series C Financing
Abionic SA, a developer of disruptive nanotechnology based rapid diagnostic solutions, announced today the successful closing of a CHF20 million Series C financing. The round was led by Pierangelo Bottinelli, Chairman of Symphony International Holdings Limited, and included Philippe Glatz (Chairman of two private hospitals), Peter Brabeck-Letmathe (former CEO and Chairman of Nestlé), ...
By Abionic SA
-
GRU, Shands HealthCare Partner on unique energy project
Gainesville Regional Utilities and Shands HealthCare are celebrating the culmination of a unique partnership to build and operate a state-of-the-art, combined heat and power plant in Gainesville, Fla. The companies hosted a dedication ceremony today for the GRU South Energy Center, the new 4.3-megawatt facility that will provide all of the electric, cooling, heating and medical-gas needs of the ...
-
Thomas Kolaras Joins SERB and BTG Specialty Pharmaceuticals as US Chief Commercial Officer
SERB and BTG Specialty Pharmaceuticals are pleased to announce that Thomas Kolaras has been named the group’s new Chief Commercial Officer for its US business. Thomas is an accomplished commercial leader with more than 25 years of US and global experience across large and mid-sized biopharmaceutical companies. His career includes a wide range of roles in marketing, sales, operations, ...
-
SERB acquires the rights to Xermelo outside US and Japan for Carcinoid Syndrome Diarrhoea
SERB is pleased to announce it has acquired the rights from Ipsen to commercialize Xermelo® (telotristat ethyl) in Europe and other countries outside the US and Japan. Financial terms of the transaction were not disclosed. Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea (CSD) in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by ...
-
Ben Watt Joins SERB and BTG as Group CFO
SERB and BTG Specialty Pharmaceuticals are pleased to announce that Ben Watt has been named the group’s new Chief Financial Officer. Ben is an experienced CFO with a track record of building global finance teams and integrating business acquisitions. Ben most recently served as CFO of Crouzet, an independent manufacturer of electronic components used in heavily regulated industries. He ...
-
SERB receives EU approval for Voraxaze (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity
SERB and BTG Specialty Pharmaceuticals announced that the European Commission has granted marketing authorisation for Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity. Voraxaze is now authorized for marketing in all members states of the European Union ...
-
First Evidence of High-Dose Methotrexate Related Toxicity in Spain Presented at Virtual ISPOR Europe 2021
The first evidence of high dose methotrexate related toxicity (HDMTX) in Spain was presented today at Virtual ISPOR Europe 2021, a global conference on healthcare economics and outcomes. Xavier Badia, MD, MPH, PhD of Omakase Consulting S.L. presented the poster titled “Epidemiology and Clinical Management of Patients with Methotrexate Toxicity in Spain Using the Delphi Technique,” ...
-
Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose. ...
-
IV Dislodgement Is a Common Problem in Vascular Access, Clinicians Say
Portsmouth, N.H. – IV dislodgement is a near-daily problem for clinicians and their patients, according to a recent focus group of vascular access experts. The clinicians also reported there is a need for better technology to mitigate the potentially serious consequences of frequent IV dislodgements. “This research discussion addressed a frustrating problem that those of us in ...
-
SERB receives positive CHMP opinion for Voraxaze (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity
SERB and BTG Specialty Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorisation for Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you